Aug. 19 at 12:47 PM
We are adding #AvitaMedical
$RCEL to the PRISM Emerging MedTech Index. The company reported this week that PermeaDerm-I hit its primary endpoint. Across 11 U.S. burn centers, the biosynthetic wound matrix PermeaDerm cost
$148.70 per percent of body surface treated against
$497.10 for cadaveric allograft, roughly
$348 in savings per percent. The clinical results held. About 94% of PermeaDerm patients reached at least 95% graft take a week after autografting, matching allograft, with no adverse events tied to the product. It also skips thawing, meshing, and tissue tracking.
https://prismmarketview.com/companies/avita-medical-inc/#about
